United States Active Pharmaceutical Ingredient Market to Grow with a CAGR of 8.76% through 2028
Growing demand
for personalized medicine and advancements in active pharmaceutical ingredient
(API) manufacturing is expected to drive the United States Active
Pharmaceutical Ingredient Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “United
States Active Pharmaceutical Ingredient Market –Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2018-2028F”, the United
States Active Pharmaceutical Ingredient Market stood at USD
21.93 Billion in 2022 and is
anticipated to project steady growth in the forecast period with a CAGR of 8.76%
through 2028. The United States Active Pharmaceutical Ingredient (API) market
is primarily driven by several key factors. The first is the rise in the
prevalence of chronic diseases, which creates a higher demand for effective
drugs and, in turn, for APIs. Advancements in pharmaceutical technologies have
improved the production and efficiency of APIs, thus fueling market growth.
Additionally, the government's increasing focus on
generic drugs, primarily to reduce healthcare expenses, has led to a surge in
the API market. Also, increased R&D activities in the pharmaceutical sector
contribute significantly to the expansion of the API market.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "United
States Active Pharmaceutical Ingredient Market”
The United States Active Pharmaceutical Ingredient
(API) market, a significant sector within the broader pharmaceutical industry,
is responsible for the production and distribution of APIs in the United
States. APIs, which are the biologically active components of pharmaceutical
drugs, play a crucial role in producing the intended therapeutic effects. This
market encompasses both branded and generic API production, covering all stages
from initial research and development (R&D), formulation, testing, and
manufacturing, to final distribution across the country.
Regulation of the US API market is primarily overseen
by the Food and Drug Administration (FDA), ensuring the safety, efficacy, and
quality of pharmaceutical products. The FDA imposes stringent guidelines and
conducts regular inspections to enforce compliance with good manufacturing
practices (GMP) and quality control standards. This regulatory oversight
contributes to the overall strength and growth of the US pharmaceutical
industry, promoting consumer safety and fostering innovation.
With a strong emphasis on research and development,
the US API market plays a vital role in advancing medical breakthroughs and
therapeutic innovations. As a crucial supply chain component, it provides the
essential building blocks for formulating and producing a wide range of
pharmaceutical drugs. The dynamic nature of the market, coupled with continuous
advancements in technology and scientific knowledge, drives the development of
new APIs, effectively supporting the ever-evolving healthcare needs of the
population.
In addition to meeting domestic demand, the US API
market also caters to global markets, contributing to the country's export
capabilities and trade relations. The reputation of US-made APIs for their
quality and compliance with international standards further enhances the
competitiveness and global standing of the US pharmaceutical industry. Overall,
the United States Active Pharmaceutical Ingredient (API) market serves as a
critical sector within the pharmaceutical industry, responsible for the
production, regulation, and distribution of APIs that form the foundation of
numerous life-saving and life-enhancing medicines. Its continuous growth and
innovation ensure that the US remains at the forefront of healthcare
advancements, positively impacting the well-being of individuals both
domestically and internationally.
The United States Active Pharmaceutical Ingredient
Market is segmented into form, drug type, source, distribution channel, therapeutic
application, company, regional distribution, and company.
Based on therapeutic applications, the cardiovascular
disease segment is expected to continue its dominance in the United States
Active Pharmaceutical Ingredient Market. This can be attributed to the high
prevalence of heart disease in the country, which necessitates a strong focus
on innovative cardiovascular therapeutic treatments. With a growing emphasis on
research and development, pharmaceutical companies are investing in
cutting-edge technologies to develop new and effective medications for
cardiovascular diseases. Furthermore, the increasing adoption of precision medicine
and personalized therapies in the field of cardiology is expected to contribute
to the growth of the cardiovascular disease segment in the US API market. The
ability to tailor treatments to individual patients based on their genetic
makeup, lifestyle, and specific disease characteristics has shown promising
results in improving patient outcomes and reducing the burden of cardiovascular
diseases.
Moreover, the rising geriatric population in the
United States is another factor driving the demand for cardiovascular
therapeutic treatments. As the elderly population continues to grow, the
incidence of age-related cardiovascular conditions such as hypertension, heart
failure, and atherosclerosis is also increasing. This demographic trend
presents significant opportunities for pharmaceutical companies to develop and
market API-based medications that cater to the specific needs of the elderly
population. The Cardiovascular Disease segment holds a prominent position in
the US API market due to the high prevalence of heart disease, the focus on
innovative treatments, and the increasing use of precision medicine. With
ongoing investments in research and development, as well as the growing
geriatric population, the segment is poised for continued growth and remains a
key driver in the pharmaceutical industry.
Based on region, the North-East region of the United
States is projected to dominate the Active Pharmaceutical Ingredient (API)
market due to several key factors. This region, encompassing states such as
Massachusetts, New York, and New Jersey, houses a large number of prominent
pharmaceutical and biotechnology companies, thereby driving significant API
production. These companies leverage the region's thriving life sciences
ecosystem, which includes access to skilled talent, state-of-the-art
facilities, and collaborative networks, to drive innovation in API development.
Moreover, the North-East region is renowned for its robust research and
development (R&D) infrastructure, including prestigious universities such
as Harvard, MIT, and Columbia, as well as renowned research institutes like the
Broad Institute and Rockefeller University. These institutions serve as hubs of
scientific excellence, fostering cutting-edge research in pharmaceuticals and
biotechnology, and contributing to advancements in API innovation.
Furthermore, supportive government policies at the
federal, state, and local levels play a crucial role in nurturing the growth of
the API market in the North-East region. These policies foster an environment
conducive to research, development, and manufacturing activities, providing
incentives for companies to invest in API production and establish a strong
presence in the region. The high demand for efficient healthcare facilities in
the North-East region, driven by a large population and a concentration of
healthcare providers, further propels the growth of the API market. The
region's hospitals, clinics, and healthcare systems require a steady supply of
high-quality APIs to meet the needs of patients, driving the demand for API
production and fostering the growth of the market.
Major companies operating in the United States Active
Pharmaceutical Ingredient Market are:
- Teva Pharmaceuticals USA
- Merck & Co., Inc.
- Pfizer Inc.
- Lupin Pharmaceuticals, Inc.
- Glenmark Pharmaceuticals, Inc.
- GlaxoSmithKline Plc
- Novartis Inc.
- Eli Lilly and Company
- AbbVie Inc.
- Sanofi-Aventis U.S. LLC
Download
Free Sample Report
Customers can also request 10% free customization on
this report.
“The future of the Active Pharmaceutical Ingredient
(API) industry in the United States is poised for significant growth and
diversification. With increasing demand for biosimilars and advancements in
recombinant technology, the industry is experiencing a transformational shift.
Moreover, the rising emphasis on precision medicine and personalized therapies
is opening up new avenues of opportunities for API manufacturers. The U.S. API
industry is on a positive trajectory, driven by various factors such as
increasing demand, technological advancements, and a focus on domestic
production. By overcoming challenges and capitalizing on opportunities, the
industry is well-positioned to play a crucial role in shaping the future of
healthcare in the United States.,” said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based management consulting firm.
“United States Active Pharmaceutical
Ingredient By
Form (Tablet, Capsule, Injection, Others), By Drug Type (Innovator, Generic), By
Source (In-house, Contract Manufacturing Organizations), By Distribution
Channel (Online, Offline), By Therapeutic Application (Cardiovascular Disease,
Anti-diabetic, Oncology, Neurological Disorders, Musculoskeletal, Others), By
Region, Competition, Forecast and& Opportunities, 2018-2028F”, has evaluated
the future growth potential of United States Active Pharmaceutical Ingredient
Market and provides statistics & information on market size, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision-makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in United States Active
Pharmaceutical Ingredient Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com